In our recently reported chemotherapy-sparing neoadjuvant trials of HER2+ breast cancer, we showed that a subset of patients with large tumors (~25–30%) achieve pCR with dual L + T therapy alone, without chemotherapy15–18. Here, ERBB2 is linked to breast carcinoma.